NASDAQ · ENLV
Healthcare · Biotechnology
$0.17
Down-$0.03 (-12.95%)
Updated Oct 24, 2026, 2:58 PM
SID Score
2.6/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · ENLV
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 23, 2026
ENLV closed at $0.17 after 21 trading sessions, down 70.98% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 23, 2026 | $0.169 | $0.1831 | $0.169 | $0.1734 | 658.99K |
| Oct 22, 2026 | $0.1961 | $0.2049 | $0.1922 | $0.1992 | 525.11K |
| Oct 21, 2026 | $0.2229 | $0.2298 | $0.20 | $0.2022 | 745.64K |
| Oct 20, 2026 | $0.215 | $0.2291 | $0.2051 | $0.2237 | 447.51K |
| Oct 19, 2026 | $0.2112 | $0.2274 | $0.1925 | $0.2074 | 607.44K |
| Oct 16, 2026 | $0.2303 | $0.2334 | $0.2045 | $0.205 | 479.69K |
| Oct 15, 2026 | $0.2202 | $0.2358 | $0.21 | $0.2242 | 560.33K |
| Oct 14, 2026 | $0.2247 | $0.228 | $0.21 | $0.2156 | 557.08K |
| Oct 13, 2026 | $0.259 | $0.2595 | $0.2212 | $0.2224 | 873.96K |
| Oct 12, 2026 | $0.26 | $0.2634 | $0.2454 | $0.253 | 892.92K |
| Oct 9, 2026 | $0.25 | $0.2826 | $0.224 | $0.254 | 2.78M |
| Oct 8, 2026 | $0.332 | $0.43 | $0.2553 | $0.277 | 32.68M |
| Oct 7, 2026 | $0.3515 | $0.3517 | $0.30 | $0.3064 | 3.9M |
| Oct 6, 2026 | $0.3737 | $0.3779 | $0.3398 | $0.3402 | 409.58K |
| Oct 5, 2026 | $0.40 | $0.408 | $0.3607 | $0.362 | 424.6K |
| Oct 2, 2026 | $0.4243 | $0.4299 | $0.38 | $0.3873 | 631.11K |
| Oct 1, 2026 | $0.492 | $0.5018 | $0.4114 | $0.4227 | 756.69K |
| Sep 30, 2026 | $0.481 | $0.58 | $0.4701 | $0.5028 | 972.23K |
| Sep 29, 2026 | $0.52 | $0.53 | $0.47 | $0.4801 | 587.74K |
| Sep 28, 2026 | $0.60 | $0.60 | $0.5027 | $0.514 | 631.02K |
| Sep 25, 2026 | $0.60 | $0.62 | $0.58 | $0.5975 | 317.47K |
The latest Smart Investors Daily articles mentioning ENLV.
Company
Market Activity
Research & News
ENLV research
Company profile and research snapshot.
Enlivex Therapeutics Ltd is an Israel-based development-stage biopharmaceutical company. It is focused on developing and commercializing an allogeneic drug pipeline for rebalancing immune hyper-responses. The company's Allocetra is an immunotherapy that is being developed to rebalance a life-threatening unbalanced immune system, using the immune system's own natural regulation mechanisms.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 3, 2026 | HC Wainwright & Co. | Buy | — |
| Apr 7, 2026 | HC Wainwright & Co. | Buy | — |
| Jan 12, 2026 | HC Wainwright & Co. | Buy | — |
| Nov 24, 2025 | D. Boral Capital | Hold | — |
| Oct 29, 2025 | D. Boral Capital | Buy | — |
No generated briefing is available yet.
Benzinga · Oct 22, 2026
Enlivex Ltd. (NASDAQ:ENLV) ("Enlivex" or the "Company"), a quality longevity company powered by a prediction markets treasury, today announced a 1-for-16 reverse split (the "Reverse Split") of
Benzinga · Oct 19, 2026
Non-clinical R&D activities to be wound down; resources to be focused on executing the Phase 2b trialWorkforce reduced by approximately 60%; management and CEO salaries reducedPlan designed to substantially reduce
ChartMill · Oct 9, 2026
Unusual volume stocks are being observed in Friday's session.
ChartMill · Oct 9, 2026
The session on Friday is off to an intriguing start with several stocks showing significant price gaps. Let's examine the gap up and gap down stocks in today's session.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning ENLV.
